Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Mach7 Technologies has added a useful new US customer, signing American Radiologist Network Inc, better known as AMRADNET, to a five-year annual subscription licence for its eUnity Viewer. The initial contract value is A$1.7 million, based on a minimum of 675,000 imaging studies a year, with volumes projected to exceed one million studies during the five-year term.

For a company with a market value sitting in the small-cap healthcare tech basket, this is not a company-making deal on its own. But investors are unlikely to view it solely through the dollar figure. The more interesting part is what the contract says about Mach7’s execution, the scalability of eUnity and the company’s attempt to shorten what has historically been a long and lumpy enterprise software sales cycle.

Why AMRADNET matters

AMRADNET is a US-based teleradiology provider whose SaaS-based Radiology Informatics Portal connects US board-certified radiologists with healthcare facilities for remote imaging interpretation and reporting. Its client base has expanded from long-term acute care and skilled nursing institutions into hospitals, outpatient centres, urgent care centres and diagnostic clinics. It is also pushing into cardiology, neurology and broader telemedicine services.

That matters because teleradiology is a volume game. The more studies flowing through a platform, the more important speed, interoperability and reliability become. Mach7’s eUnity Viewer is designed for high-volume diagnostic image access, which makes the AMRADNET win a useful reference point in a US market where remote care and distributed reporting models continue to gain ground.

The deployment rabbit pulled from the hat

The standout metric is not only the A$1.7 million contract value. It is the expected time to first productive use: within 45 days. Mach7 says this is a significant reduction from its typical 12-month deployment timeline, attributing the improvement to the removal of silos and a restructuring of its sales and services teams.

For investors, that is the sort of operational detail worth lingering over. Enterprise imaging software sales can be painfully slow, with procurement, integration, compliance and workflow redesign all conspiring to make revenue conversion feel like watching paint dry in a dark room. A 45-day expected go-live timetable, if repeated elsewhere, could improve revenue visibility, customer onboarding and cash conversion.

Chief executive and managing director Teri Thomas framed the deal as both a customer win and an execution marker, saying AMRADNET was building “a scalable and rapidly growing teleradiology platform” and that the speed from evaluation to first productive use highlighted both AMRADNET’s operational focus and the strength of eUnity in “fast-moving, high-volume imaging environments”.

Recurring revenue, but mind the fine print

The contract is structured as an annual subscription licence, which is positive for investors who prefer repeatable revenue over one-off software sales. However, the released details describe an initial contract value rather than spelling out potential upside mechanics if AMRADNET’s imaging volumes exceed the minimum threshold. So while the projected lift beyond one million studies a year is encouraging, investors should avoid assuming a linear revenue kicker unless Mach7 provides more detail.

Mach7’s broader platform combines a Vendor Neutral Archive, the eUnity Enterprise Diagnostic Viewer and its Flamingo suite of modules, supporting workflow, interoperability and data management across complex healthcare environments. The company says its software is built for interoperability and scalability, while also being aligned with cloud ecosystems including Amazon Web Services.

Market reaction says investors noticed

The key question now is repeatability. One fast deployment is interesting. Several would be evidence. Mach7 has told investors it is changing the way it sells and implements software. AMRADNET gives the company a live test case for that claim in a commercially relevant part of the US healthcare system.

For now, the deal is a tidy contract with a potentially larger message: Mach7 is trying to turn enterprise imaging from a slow-moving hospital IT grind into a more scalable, subscription-led growth story. In small-cap health tech, where promises often travel faster than implementations, shaving deployment time from 12 months to 45 days is the sort of thing that will get investors peering more closely at the scan.

Racura Oncology has passed the first formal safety checkpoint in its CPACS Phase 1 trial, with the Safety Review Committee clearing the company to escalate RC220 to the next planned dose level of 80mg/m². For a clinical-stage biotech, this is not a champagne cork moment on efficacy, but it is a meaningful progression through the part of drug development where the market is mostly asking one question: can patients tolerate the stuff?

The answer so far is encouraging. The first three patients in Cohort 1, all with advanced metastatic solid tumours, received RC220 at 40mg/m². The committee found no treatment-related safety concerns, no dose-limiting toxicities and an acceptable safety profile during the observation period. Racura also says all trial patients remain alive, despite their advanced metastatic disease status at enrolment.

Why the doxorubicin angle matters

The CPACS study is testing RC220 in combination with doxorubicin, a long-used chemotherapy that remains potent but is limited by its well-known potential for heart toxicity. Cohort 1 patients were treated first with RC220 alone, then up to six cycles of RC220 plus doxorubicin at the standard-of-care dose of 60mg/m². That matters because Racura is not merely trying to show RC220 can be layered onto existing therapy without making things worse. The larger commercial idea is that RC220 may deliver both anticancer activity and cardioprotection.

That is a neat proposition, if it holds up. Oncology is full of promising mechanisms that trip over tolerability, combination safety, or the cold mathematics of small patient numbers. But the ability to move to the 80mg/m² cohort keeps the clinical thesis alive and gives Racura more data to work with.

Chief executive and managing director Dr Daniel Tillett called the early safety readout “highly encouraging”, pointing particularly to the absence of dose-limiting toxicities when RC220 was combined with standard-dose doxorubicin.

The protocol tweak adds an extra readout

The next cohort will use an updated trial protocol, with an initial lead-in safety monotherapy cycle of doxorubicin before RC220 is added. The practical effect is that Racura can assess RC220’s potential cardioprotective effect using a blood-based molecular test. Patient screening is underway across Australia, Hong Kong and South Korea, giving the company a multi-region recruitment base rather than relying on a single geography.

For investors, this is the useful bit. The trial is still early, but the updated design potentially makes the data package richer. Safety is the first gate. A signal on cardioprotection, if it emerges, would be a more differentiated claim.

The broader Racura story

Racura describes itself as a Phase 3 clinical-stage biopharmaceutical company. Its lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that the company says acts mainly through G4-DNA and RNA binding, leading to silencing of MYC, a key cancer growth regulator. RC220 is Racura’s proprietary formulation of that asset. The company is pursuing programs in acute myeloid leukaemia, mutant EGFR non-small cell lung cancer and the doxorubicin combination program in solid tumours.

The stock is no longer a tiddler, Racura has a market capitalisation of about $509 million.

What to watch next

The next inflection points are straightforward: whether Cohort 2 recruits smoothly, whether the 80mg/m² dose remains tolerable, and whether the pharmacokinetic and biomarker data strengthen the case for RC220’s role alongside doxorubicin. The patient number is still tiny, so extrapolating too much would be a mug’s game. But in early oncology, the first job is to keep the trial moving without safety alarms.

On that score, Racura has done what it needed to do. The bigger question is whether RC220 can graduate from “safe enough to keep testing” to a therapy with a compelling clinical and commercial reason to exist.

Swift TV has taken another step from promise to proof, with the enterprise entertainment and engagement platform provider completing its first four aged-care site rollouts for Australia’s largest aged-care provider and securing a further three sites under the same three-year recurring revenue model.

For a company with a market capitalisation of about $11.25 million, even modest commercial traction matters. This is not BHP discovering another Pilbara. But for a microcap technology stock, converting a master services agreement into commissioned sites and recurring subscription revenue is the stuff investors watch closely.

From rollout risk to revenue

The key point is not simply that Swift has installed its Swift TV platform at four aged-care sites. It is that those sites have moved through installation and commissioning, which is when the company says recurring subscription revenue begins.

That distinction is worth making. Small technology companies are rarely short of pilots, memorandums of understanding and “pathways” to large addressable markets. The harder bit is getting customers live, paid and ready to expand. Swift says the initial rollout under its master services agreement has now been completed across the first four sites, with a further three sites committed by the customer under the existing three-year, per-site model.

That takes the contracted deployment footprint to seven sites, assuming the additional three proceed through commissioning as expected. The dollars were not disclosed, so investors are left without the most important number: revenue per site. Still, the shift to recurring subscription revenue gives the story a more measurable spine than one-off hardware or installation sales.

Why aged care matters

Swift’s flagship product is positioned as an all-in-one connected TV platform for enterprise environments, including mining, oil and gas, aged care and hospitality. In aged care, the pitch is not just Netflix for Nan. The platform is designed to combine entertainment, communication and engagement, while supporting integrations that can improve operational outcomes for facility operators.

That matters because aged-care providers run distributed portfolios, often with standardised procurement needs across many facilities. Win one site and a supplier has a reference case. Win several and the conversation can move from novelty to network-wide utility.

Swift says the customer operates a large national portfolio of sites, leaving scope for further rollout. That is the carrot here. The initial seven sites are meaningful for validation, but the investor question is whether Swift can convert the broader portfolio opportunity into a material recurring revenue base.

Management’s message: repeatability

Chief executive Brian Mangano called the completion of the initial rollout “an important step in the commercialisation of Swift TV” and said it validated the company’s ability to deploy across large, multi-site customer environments.

More importantly for investors, he pointed to the revenue model. “Importantly, we are now transitioning into recurring subscription revenue as sites are commissioned, and the early commitment to additional sites highlights the strength of customer demand and expansion potential within this agreement,” Mangano said.

He added that Swift sees the model as repeatable across its customer base as deployments scale.

That is the nub of the investment case. Swift does not need every aged-care home in Australia to become a cash machine overnight. It needs to demonstrate that once its platform lands inside a portfolio customer, additional sites can be added without reinventing the wheel each time. Repeatability is where software-style economics can start to show, provided gross margins, support costs and customer churn behave themselves.

The questions investors will ask next

There are still gaps. Swift did not disclose contract value, annual recurring revenue per site, expected rollout timing for the additional three sites, gross margins, or whether implementation costs are front-loaded. Without those details, investors cannot yet judge the financial weight of the win.

Nor should the customer’s size obscure execution risk. Large aged-care groups can offer expansion potential, but they can also move slowly, demand customisation and squeeze suppliers on price. Swift will need to show that deployments can be done efficiently and that each new site adds revenue without dragging in too much cost.

For now, the update is a credible commercial marker. It shows a live multi-site deployment, early customer expansion and the beginning of recurring subscription revenue under a three-year model. For a small ASX technology company, that is a more useful development than another glossy strategy deck.

The next test is scale. Seven sites are a start. A broader portfolio rollout would be a story.

Fluence Corporation has added another US industrial water project to its order book, securing a contract worth about US$3.7 million to design and build a water treatment plant for a prominent manufacturer in Texas. The plant will use ultrafiltration and reverse osmosis technologies and is expected to be installed and fully operational by the end of 2026.

For investors, the dollar value is not company-transforming on its own. But the strategic signal is more interesting. Fluence is pitching itself into the intersection of industrial water security, decentralised treatment and climate-stressed US manufacturing regions. Texas, with its periodic droughts, fast-growing industrial base and pressure on municipal water systems, is a useful proving ground.

The project will treat groundwater from an on-site well for use as cooling tower makeup water. Once complete, the facility is expected to produce up to 1.5 million gallons per day, reducing the customer’s reliance on municipal water supplies. Fluence says the system is designed to achieve more than 90% recovery of feedwater, which matters because industrial customers are not just trying to access water, they are increasingly trying to squeeze more output from every litre available.

Water security becomes an operating issue

Chief executive and managing director Ben Fash framed the contract as part of a broader shift among industrial manufacturers facing water scarcity.

“Industrial manufacturers across Texas and other drought-stricken regions in the US are increasingly confronting the reality that water security could become an operational issue,” Fash said. He added that advanced water treatment could help industry maintain production while supporting broader conservation goals during periods of extreme drought.

That is the nub of the investment case Fluence is trying to sharpen. Water treatment is no longer purely a municipal infrastructure story, nor only an environmental compliance cost. For some industrial users, particularly in water-stressed regions, supply reliability is becoming a production risk. Cooling towers are not glamorous, but if they are short of water, the factory does not run as intended.

Fluence’s pitch is that its quick-to-deploy systems can meet tight quality requirements while helping customers become less dependent on public networks. That decentralised angle is important. Rather than waiting for large civic infrastructure upgrades, industrial users can install dedicated treatment capacity on site.

Industrial growth is the main prize

Fluence says the Texas contract forms part of its growing portfolio of industrial projects in the US. The company describes itself as active in wastewater treatment and reuse, high-strength wastewater treatment, wastewater-to-energy, industrial and drinking water markets, with standardised products including Aspiral, NIROBOX, SUBRE and Nitro. It also offers operations and maintenance support, Build Own Operate structures and other recurring revenue models.

That recurring revenue point is worth watching. One-off equipment contracts can be lumpy, especially for a smaller ASX-listed company. Investors will want to see whether Fluence can turn project wins into a steadier base of service, maintenance or long-term operating revenue. A US$3.7 million plant is welcome. A repeatable platform across multiple industrial customers would be more valuable.

Fash was clearly leaning into that ambition, saying Fluence hopes to provide solutions to “many other industrial customers facing similar challenges in the US and abroad”.

Market context for FLC holders

Fluence remains a small-cap stock, so contract news can loom larger than it would for a bigger industrial.

That size cuts both ways. Smaller contracts can be meaningful for revenue visibility, but execution risk is also magnified. Investors will want to track whether the plant is delivered on schedule, whether margins are attractive, and whether the project leads to follow-on work in Texas or other drought-affected US regions.

The key point is that Fluence is not merely selling a piece of water kit. It is selling operational resilience to manufacturers whose water supply assumptions are becoming less comfortable. If management can convert that theme into a broader pipeline of industrial orders, the Texas win may prove more significant than its headline contract value suggests.

Archer Materials has given investors another breadcrumb on the long road from deep-tech promise to manufacturable quantum devices, saying it remains on track to demonstrate a working qubit this year while pushing its graphene-based device work toward wafer-scale production.

For a company such as Archer, the headline is not merely that the qubit program is progressing. The more commercially important message is that management is trying to drag the technology out of the lab coat phase and into the world of repeatable semiconductor manufacturing. That is where things become more interesting for investors, because quantum technologies are only valuable at scale if they can be made reliably, consistently and, eventually, economically.

Archer says it has now completed multiple design, fabrication and testing cycles across its quantum device program. These cycles have helped refine device structures, validate critical components and build confidence that its processes could be compatible with larger-scale semiconductor manufacturing.

Why wafer-scale matters

Wafer-scale manufacturing is a dry phrase, but it is doing a lot of heavy lifting here. It means Archer is thinking about how its devices might be produced using processes closer to those already used by semiconductor foundries, rather than as one-off laboratory specimens.

The company says the move toward wafer-scale processes should support improved consistency, reproducibility across fabrication runs, higher throughput and better compatibility with industrial foundry environments.

For investors, that matters because the quantum sector is littered with technically impressive claims that struggle to make the jump into manufacturable hardware. A single qubit demonstration would be a scientific milestone. A pathway to manufacture would be the more commercially relevant bridge.

Archer chief executive Dr Simon Ruffell described the progress toward wafer-scale manufacturing as an “important technical and strategic milestone”, adding that the company is working toward technologies that can integrate into existing semiconductor supply chains.

The graphene angle

Archer’s qubit program is built around graphene and semiconductor device capabilities. Recent work has focused on characterising graphene materials and fabricated devices, with the data feeding back into future qubit designs and processing methods.

That sounds wonky, because it is. But the investment relevance is straightforward: Archer is trying to build a repeatable knowledge base around how these materials behave when turned into functional devices.

The company is also careful to point out that the same underlying capabilities may have uses beyond quantum computing. Management namechecks potential applications in terahertz sensing, photonics, artificial intelligence infrastructure, cloud technologies and other quantum-enabled systems.

That is useful optionality. It also means investors should judge Archer not only on the binary question of whether it produces a working qubit this year, but on whether its broader platform of graphene and semiconductor know-how can generate commercial pathways in adjacent markets.

The investor read-through

Archer is still a pre-commercial deep-tech story, so the usual caveats apply. Technical progress does not automatically translate into revenue, customers, margins or defensible market share. Quantum computing remains a brutally complex field, and global competition is hardly thin on the ground.

However, the update gives investors a clearer sense of the next gating item. Archer is aiming to demonstrate a working qubit, then increasingly focus on transferring fabrication processes into foundry-compatible environments and improving qubit performance.

That sequencing is important. First prove the device can work. Then prove it can be improved. Then prove it can be made in a way that fits with the semiconductor ecosystem. Only then does the bigger commercial conversation become more tangible.

Archer has a market capitalisation of about $76.45 million, placing it firmly in the speculative end of the technology market rather than the institutional heavyweight category.

A milestone year, but not the finish line

The key phrase for investors is “on track”. Archer says it remains on track to demonstrate a working qubit this year, which would be a major credibility marker for the company’s quantum technology program.

But the real prize is not a science trophy for the cabinet. It is whether Archer can turn that milestone into a manufacturable technology platform with relevance across computing, sensing and advanced semiconductor markets.

For now, Archer has strengthened the narrative that it is not merely tinkering at the edges of quantum hardware. It is trying to build devices that could, in time, be made through scalable semiconductor processes. That is still a long road, but at least the road now has a few more signposts.